anipamil profile

anipamil: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	54966
CHEMBL ID	2104548
SCHEMBL ID	247837
MeSH ID	M0131846

Synonym
anipamil
anipamil [inn]
einecs 280-213-5
anipamilo [spanish]
2-(3-((m-methoxyphenethyl)methylamino)propyl)-2-(m-methoxyphenyl)tetradecanenitrile
anipamilum [latin]
2-(3-methoxyphenyl)-2-[3-[2-(3-methoxyphenyl)ethyl-methylamino]propyl]tetradecanenitrile
83200-10-6
unii-9y54wzv1cj
anipamilo
anipamilum
9y54wzv1cj ,
CHEMBL2104548
anipamil [mart.]
anipamil [who-dd]
benzeneacetonitrile, .alpha.-dodecyl-3-methoxy-.alpha.-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-
SCHEMBL247837
0b09laq38g ,
74au98p8pi ,
unii-74au98p8pi
unii-0b09laq38g
anipamil, (-)-
85247-61-6
85247-63-8
benzeneacetonitrile, alpha-dodecyl-3-methoxy-alpha-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-, (-)-
benzeneacetonitrile, alpha-dodecyl-3-methoxy-alpha-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-, (+)-
anipamil, (+)-
benzeneacetonitrile, .alpha.-dodecyl-3-methoxy-.alpha.-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-, (+)-
benzeneacetonitrile, .alpha.-dodecyl-3-methoxy-.alpha.-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-, (-)-
CS-6769
HY-U00044
Q4765248
2-(3-((3-methoxyphenethyl)(methyl)amino)propyl)-2-(3-methoxyphenyl)tetradecanenitrile
DTXSID70868699
AKOS040741148

Research Excerpts

Effects

Anipamil has a more favourable ratio of antiarrhythmic to hypotensive effects when compared with verapamil.

Excerpt	Reference	Relevance
"Anipamil has a more favourable ratio of antiarrhythmic to hypotensive effects when compared with verapamil."	( Actions of the verapamil analogues, anipamil and ronipamil, against ischaemia-induced arrhythmias in conscious rats. Curtis, MJ; Walker, MJ; Yuswack, T, 1986)	1.27
"Anipamil may have been proarrhythmic in the early phase of arrhythmias and only moderately antiarrhythmic, if at all, in the later phase.(ABS"	( Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995)	1.4
"Anipamil has a more favourable ratio of antiarrhythmic to hypotensive effects when compared with verapamil."	( Actions of the verapamil analogues, anipamil and ronipamil, against ischaemia-induced arrhythmias in conscious rats. Curtis, MJ; Walker, MJ; Yuswack, T, 1986)	1.27

Treatment

Pretreatment with anipamil induced a negative inotropic effect under normoxic conditions. Reduced the rate and extent of depletion of ATP and creatine phosphate during ischemia. Maintained mitochondrial function and calcium homeostasis.

Excerpt	Reference	Relevance
"The anipamil-treated group exhibited significantly greater protection of renal function than did the hydralazine-treated group for the same level of blood pressure control."	( Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. Chan, L; Jarusiripipat, C; Schrier, RW; Shapiro, JI, 1992)	1.02
"Pretreatment with anipamil induced a negative inotropic effect under normoxic conditions; reduced the rate and extent of depletion of ATP and creatine phosphate during ischemia, with an incomplete restoration of the nucleotides after reperfusion; maintained mitochondrial function and calcium homeostasis during ischemia and reperfusion; reduced the rate of CPK release; and improved the recovery of ventricular function on reperfusion."	( Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil. Ceconi, C; Curello, S; Ferrari, R; Ghielmi, S; Raddino, R; Visioli, O, 1989)	0.85
"Pretreatment with anipamil altered neither left ventricular developed pressure under normoxic conditions nor the rate and extent of depletion of adenosine triphosphate (ATP) and creatine phosphate during ischemia."	( Protective effect of pretreatment with the calcium antagonist anipamil on the ischemic-reperfused rat myocardium: a phosphorus-31 nuclear magnetic resonance study. Kirkels, JH; Meijler, FL; Ruigrok, TJ; Van Echteld, CJ, 1988)	0.84

Dosage Studied

Anipamil displaced the dose-response curves for the positive inotropic effect of (0.1 microM) When given intravenously (2 mg kg-1 body weight 1 h before the animals were killed)

Excerpt	Relevance	Reference
"1 microM) to isolated hearts, or when given intravenously (2 mg kg-1 body weight 1 h before the animals were killed), anipamil displaced the dose-response curves for the positive inotropic effect of (0."	( The Ca2+ -antagonist and binding properties of the phenylalkylamine, anipamil. Dillon, JS; Nayler, WG, 1988)	0.72
" Initial dose-response studies for anipamil (0."	( Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995)	0.96

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (51.72)	18.7374
1990's	14 (48.28)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (9.68%)	5.53%
Reviews	1 (3.23%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (87.10%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gallopamil Gallopamil: Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.	6.98	1	0	benzenes; organic amino compound
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	6.97	1	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
bay-k-8644 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.	2.38	2	0	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	3.36	7	0	aromatic ether; nitrile; polyether; tertiary amino compound
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	1.98	1	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	1.97	1	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	7.38	2	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.37	1	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	1.97	1	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
4-desmethoxyverapamil [no description available]	1.97	1	0
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	1.96	1	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	1.98	1	0
phosphocreatine Phosphocreatine: An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996). phosphagen : Any of a group of guanidine or amidine phosphates that function as storage depots for high-energy phosphate in muscle with the purpose of regenerating ATP from ADP during muscular contraction.. N-phosphocreatine : A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.	2.37	2	0	phosphagen; phosphoamino acid	human metabolite; mouse metabolite
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	1.97	1	0
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	1.97	1	0

Condition	Relationship Strength	Studies	Trials
Angor Pectoris [description not available]	4.33	2	2
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	4.33	2	2
Arrhythmia [description not available]	7.67	3	0
Heart Disease, Ischemic [description not available]	3.77	2	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.67	3	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	8.77	2	1
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.38	2	0
Left Ventricular Hypertrophy [description not available]	1.98	1	0
Cardiovascular Stroke [description not available]	2.38	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.38	2	0
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	1.98	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.39	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1	0
Familial Combined Hyperlipidemia [description not available]	1.98	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	3.59	3	0
Hyperlipidemia, Familial Combined A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.	1.98	1	0
Blood Pressure, High [description not available]	3.77	2	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	8.77	2	1
Injury, Myocardial Reperfusion [description not available]	2.67	3	0
Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	1.98	1	0
Coronary Heart Disease [description not available]	3.35	7	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	3.35	7	0
Calcification, Pathologic [description not available]	2.89	1	0
Calcinosis Pathologic deposition of calcium salts in tissues.	2.89	1	0
Injury, Ischemia-Reperfusion [description not available]	1.97	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	1.97	1	0
Cardiomyopathies, Primary [description not available]	1.97	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1.97	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	6.97	1	0
Anoxemia [description not available]	1.96	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	1.96	1	0

anipamil

Description

Cross-References

Synonyms (35)

Research Excerpts

Effects

Treatment

Dosage Studied

Research

Studies (29)

Market Indicators

Research Demand Index: 20.18

Study Types

anipamil

Description

Cross-References

Synonyms (35)

Research Excerpts

Effects

Treatment

Dosage Studied

Research

Studies (29)

Market Indicators

Research Demand Index: 20.18

Study Types

Related Drugs (15)

Related Conditions (31)